Transforming the landscape of multiple myeloma (MM) with CAR T-cell therapies FINAL

Learning objective:

After attending this symposium delegates should be able to:

• Describe how CAR T-cell therapies are advancing the treatment options for patients with MM
• Discuss practical considerations about the use of CAR T-cell therapy for patients with MM

Faculty:

• Philippe Moreau (France)
• Kwee Yong (UK)
• Inger Nijhof (The Netherlands)